Torcand-8/Torcand-16

Candesartan cilexetil

Essential HTN. Heart failure & impaired left ventricular systolic function (left ventricular ejection fraction of 40%) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.

HTN Initially 8 mg once daily, can be increased to 16 mg once daily. Max: 32 mg once daily. Elderly, patient w/ renal & mild to moderate hepatic impairment, on hemodialysis Initially 4 mg. Heart failure Initially 4 mg once daily. Max: 32 mg once daily.

May be taken with or without food.

Hypersensitivity. Severe hepatic impairment &/or cholestasis. Pregnancy & lactation.

Periodic monitoring of serum K & creatinine levels in patients w/ renal impairment; assessment of renal function, especially in elderly ≥75 yr & w/ impaired renal function in patients w/ heart failure. Monitor BP in patients on hemodialysis. Concomitant therapy w/ ACE inhibitors in heart failure. May increase blood urea & serum creatinine in patients w/ bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. Kidney transplantation. Hypotension during anesth & surgery. Aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy. Not recommended in primary hyperaldosteronism. Concomitant use w/ K-sparing diuretics, K supplements, salt substitutes containing K, & heparin. Hyperkalemia. Excessive BP decrease in patients w/ ischemic cardiopathy & cerebrovascular disease could result in MI or stroke. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive or operate machinery. Childn <18 yr.

Resp infection; leukopenia, neutropenia & agranulocytosis; hyperkalemia, hyponatremia; dizziness/vertigo, headache; cough; nausea; increased liver enzymes, abnormal hepatic function or hepatitis; angioedema, rash, urticaria, pruritus; back pain, arthralgia, myalgia; renal impairment, including renal failure in susceptible patients.

May increase K levels w/ K-sparing diuretics, K supplements, salt substitute containing K, heparin. Reversible increases in lithium serum conc & toxicity. Attenuation of antihypertensive effect w/ NSAIDs [ie, selective COX-2 inhibitors, ASA (>3 g/day) & non-selective NSAIDs]. Increased risk of worsening of renal function, including possible acute renal failure & increase in serum K, especially in patients w/ poor preexisting renal function w/ NSAIDs.

Angiotensin II Antagonists

C09CA06 - candesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx